Quell Therapeutics

Founded: 2019
CEO: Iain McGill
Founders: Giovanna Lombardi
Marc Martinez-Llordella
Alberto Sanchez-Fueyo
Hans Stauss
Emma Morris
Elmar Jaeckel
Shareholding: 33.7%
Stage: Clinical
Employees: c.150
Raised in Series B financing: $156m
Clinical trials: 1

Unless stated all financials at 31 December 2025.

Quell website

Quell Therapeutics was founded with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system.

Quell was founded in partnership with six prominent immunological experts from King’s College London, University College London and Hannover Medical School, and is led by Iain McGill, a seasoned pharmaceutical and biotech executive.

Tregs are capable of down regulating the immune system by ‘putting on a brake’ to prevent over activation and resultant pathological immune responses.

Quell is employing proprietary and innovative technologies to genetically enhance Tregs, with the goal to leverage the unique potential of Tregs to reinstate immune balance, bringing long-lasting control to patients with severe immune diseases.

Best ideas Pre-clinical Clinical Late Clinical BLA

Quell Therapeutics

QEL-001 - Liver transplant

Syncona team

Elisa Petris

Elisa is a Managing Partner of Syncona Investment Management Limited. She is a Director on the Board of Quell Therapeutics, Beacon Therapeutics and Forcefield Therapeutics and was previously on the Board of former portfolio companies Blue Earth Diagnostics and Neogene, and of current portfolio company Achilles Therapeutics. She was closely involved in the foundation of Quell, Blue Earth, Achilles…

View Elisa's biography

Position

Board member

Qualification

PhD